Welkom bij Scalda & Bohn Stafleu van Loghum
Scalda heeft ervoor gezorgd dat je Mijn BSL eenvoudig en snel kunt raadplegen.Je kunt de producten hieronder links aanschaffen en rechts inloggen.
25-03-2025 | Review
Disutilities of treatment-related attributes for type 2 diabetes mellitus: a systematic review
Auteurs: Shitong Xie, Xinran Liu, Meixuan Li, Jing Wu
Gepubliceerd in: Quality of Life Research
Log in om toegang te krijgenshare
DELEN
Deel dit onderdeel of sectie (kopieer de link)
-
Optie A:
-
Optie B:Deel de link per e-mail
Abstract
Objectives
To synthesize the literature on eliciting disutilities associated with treatment-related attributes in type 2 diabetes (T2DM).
Methods
We searched Medline, Embase, Cochrane Library, PsycINFO, EconLit and CINAHL databases from inception to December, 2024. This systematic review followed PRISMA guidelines, quality and risk of bias of the included studies were assessed using the NICE and ROBINS-I checklist.
Results
Nine studies involving 59 to 4060 participants were included and most studies (n=6) were conducted in the UK. The perspective of preference included T2DM patients (n=7) and the general public (n=3), with one study included both. Elicitation approaches used were time trade-off (n=5) and standard gamble (n=4). Eight treatment-related attributes were identified, including weight change (n=5), dosing frequency (n=4), gastrointestinal side effects (n=2), flexible dosing (n=2), administration requirement (i.e., reconstitution, waiting, and needle handling) (n=2), injection site reaction (n=1), fear of hypoglycemia (n=1), and HbA1c levels (n=1). For the attribute of weight change, the (dis)utility value ranged from -0.106 to 0.047. Respondents showed a preference for weekly over daily administration (range: 0.023 to 0.095), once-daily over multiple-daily (range: 0.015 to 0.123). The (dis)utility values for the rest of six attributes ranged from -0.04 to 0.034.
Conclusions
This review provides evidence synthesize of published disutilities related to T2DM treatment-related attributes which have a nonnegligible effect. Weight change and dosing frequency were the most reported with the largest impact. Given the considerable heterogeneity in current studies, care should be taken in selecting appropriate estimates between different elicitation methods, populations and countries.
Log in om toegang te krijgen
Literatuur
1.
go back to reference Li, Y., Teng, D., Shi, X., Qin, G., Qin, Y., Quan, H., Shi, B., Sun, H., Ba, J., Chen, B., Du, J., He, L., Lai, X., Li, Y., Chi, H., Liao, E., Liu, C., Liu, L., Tang, X., Tong, N., Wang, G., Zhang, J. A., Wang, Y., Xue, Y., Yan, L., Yang, J., Yang, L., Yao, Y., Ye, Z., Zhang, Q., Zhang, L., Zhu, J., Zhu, M., Ning, G., Mu, Y., Zhao, J., Teng, W., & Shan, Z. (2020). Prevalence of diabetes recorded in Mainland China using 2018 diagnostic criteria from the American diabetes association: National cross sectional study. Bmj, 369, m997. https://doi.org/10.1136/bmj.m997CrossRefPubMedPubMedCentral
Li, Y., Teng, D., Shi, X., Qin, G., Qin, Y., Quan, H., Shi, B., Sun, H., Ba, J., Chen, B., Du, J., He, L., Lai, X., Li, Y., Chi, H., Liao, E., Liu, C., Liu, L., Tang, X., Tong, N., Wang, G., Zhang, J. A., Wang, Y., Xue, Y., Yan, L., Yang, J., Yang, L., Yao, Y., Ye, Z., Zhang, Q., Zhang, L., Zhu, J., Zhu, M., Ning, G., Mu, Y., Zhao, J., Teng, W., & Shan, Z. (2020). Prevalence of diabetes recorded in Mainland China using 2018 diagnostic criteria from the American diabetes association: National cross sectional study. Bmj, 369, m997. https://doi.org/10.1136/bmj.m997CrossRefPubMedPubMedCentral
2.
go back to reference Magliano, D. J., Boyko, E. J., & Committee, I. (2021). D. F. D. a. T. E. S. IDF Diabetes Atlas. Idf diabetes atlas. International Diabetes Federation, 2021.
Magliano, D. J., Boyko, E. J., & Committee, I. (2021). D. F. D. a. T. E. S. IDF Diabetes Atlas. Idf diabetes atlas. International Diabetes Federation, 2021.
3.
go back to reference Einarson, T. R., Acs, A., Ludwig, C., & Panton, U. H. (2018). Economic burden of cardiovascular disease in type 2 diabetes: A systematic review. Value in Health: the Journal of the international Society for Pharmacoeconomics and Outcomes Research, 21(7), 881–890. https://doi.org/10.1016/j.jval.2017.12.019CrossRefPubMed
Einarson, T. R., Acs, A., Ludwig, C., & Panton, U. H. (2018). Economic burden of cardiovascular disease in type 2 diabetes: A systematic review. Value in Health: the Journal of the international Society for Pharmacoeconomics and Outcomes Research, 21(7), 881–890. https://doi.org/10.1016/j.jval.2017.12.019CrossRefPubMed
4.
go back to reference Laxy, M., Becker, J., Kähm, K., Holle, R., Peters, A., Thorand, B., Schwettmann, L., & Karl, F. M. (2021). Utility decrements associated with diabetes and related complications: Estimates from a Population-Based study in Germany. Value in Health: the Journal of the international Society for Pharmacoeconomics and Outcomes Research, 24(2), 274–280. https://doi.org/10.1016/j.jval.2020.09.017CrossRefPubMed
Laxy, M., Becker, J., Kähm, K., Holle, R., Peters, A., Thorand, B., Schwettmann, L., & Karl, F. M. (2021). Utility decrements associated with diabetes and related complications: Estimates from a Population-Based study in Germany. Value in Health: the Journal of the international Society for Pharmacoeconomics and Outcomes Research, 24(2), 274–280. https://doi.org/10.1016/j.jval.2020.09.017CrossRefPubMed
5.
go back to reference Committee, A. D., & a., P. P. (2023). 9. Pharmacologic approaches to glycemic treatment: Standards of care in Diabetes—2024. Diabetes Care, 47(Supplement_1), S158–S178. https://doi.org/10.2337/dc24-S009CrossRef
Committee, A. D., & a., P. P. (2023). 9. Pharmacologic approaches to glycemic treatment: Standards of care in Diabetes—2024. Diabetes Care, 47(Supplement_1), S158–S178. https://doi.org/10.2337/dc24-S009CrossRef
6.
go back to reference Blonde, L., Dipp, S., & Cadena, D. (2018). Combination Glucose-Lowering therapy plans in T2DM: Case-Based considerations. Adv Ther, 35(7), 939–965. https://doi.org/10.1007/s12325-018-0694-0CrossRefPubMedPubMedCentral
Blonde, L., Dipp, S., & Cadena, D. (2018). Combination Glucose-Lowering therapy plans in T2DM: Case-Based considerations. Adv Ther, 35(7), 939–965. https://doi.org/10.1007/s12325-018-0694-0CrossRefPubMedPubMedCentral
7.
go back to reference Boye, K. S., Matza, L. S., Walter, K. N., Van Brunt, K., Palsgrove, A. C., & Tynan, A. (2011). Utilities and disutilities for attributes of injectable treatments for type 2 diabetes. The European Journal of Health Economics, 12(3), 219–230. https://doi.org/10.1007/s10198-010-0224-8CrossRefPubMed
Boye, K. S., Matza, L. S., Walter, K. N., Van Brunt, K., Palsgrove, A. C., & Tynan, A. (2011). Utilities and disutilities for attributes of injectable treatments for type 2 diabetes. The European Journal of Health Economics, 12(3), 219–230. https://doi.org/10.1007/s10198-010-0224-8CrossRefPubMed
8.
go back to reference Valentine, W., Norrbacka, K., & Boye, K. S. (2022). Evaluating the impact of therapy on quality of life in type 2 diabetes: A literature review of utilities associated with Treatment-Related attributes. Patient Relat Outcome Meas, 13, 97–111. https://doi.org/10.2147/prom.S322390CrossRefPubMedPubMedCentral
Valentine, W., Norrbacka, K., & Boye, K. S. (2022). Evaluating the impact of therapy on quality of life in type 2 diabetes: A literature review of utilities associated with Treatment-Related attributes. Patient Relat Outcome Meas, 13, 97–111. https://doi.org/10.2147/prom.S322390CrossRefPubMedPubMedCentral
9.
go back to reference Xie, S., Wu, J., & Xie, F. (2022). Population norms for SF-6Dv2 and EQ-5D-5L in China. Applied Health Economics and Health Policy, 20(4), 573–585. https://doi.org/10.1007/s40258-022-00715-2CrossRefPubMed
Xie, S., Wu, J., & Xie, F. (2022). Population norms for SF-6Dv2 and EQ-5D-5L in China. Applied Health Economics and Health Policy, 20(4), 573–585. https://doi.org/10.1007/s40258-022-00715-2CrossRefPubMed
10.
go back to reference Xie, S., Wu, J., & Chen, G. (2022). Discrete choice experiment with duration versus time trade-off: A comparison of test-retest reliability of health utility elicitation approaches in SF-6Dv2 valuation. Quality of Life Research, 31(9), 2791–2803. https://doi.org/10.1007/s11136-022-03159-2CrossRefPubMed
Xie, S., Wu, J., & Chen, G. (2022). Discrete choice experiment with duration versus time trade-off: A comparison of test-retest reliability of health utility elicitation approaches in SF-6Dv2 valuation. Quality of Life Research, 31(9), 2791–2803. https://doi.org/10.1007/s11136-022-03159-2CrossRefPubMed
11.
go back to reference Hall, F., De Freitas, H. M., Kerr, C., Ito, T., Nafees, B., Lloyd, A. J., Penton, J., Hadi, M., Lanar, S., & Pham, T. P. (2019). Estimating utilities/disutilities for high-risk metastatic hormone-sensitive prostate cancer (mHSPC) and treatment-related adverse events. Quality of Life Research, 28(5), 1191–1199. https://doi.org/10.1007/s11136-019-02117-9CrossRefPubMedPubMedCentral
Hall, F., De Freitas, H. M., Kerr, C., Ito, T., Nafees, B., Lloyd, A. J., Penton, J., Hadi, M., Lanar, S., & Pham, T. P. (2019). Estimating utilities/disutilities for high-risk metastatic hormone-sensitive prostate cancer (mHSPC) and treatment-related adverse events. Quality of Life Research, 28(5), 1191–1199. https://doi.org/10.1007/s11136-019-02117-9CrossRefPubMedPubMedCentral
12.
go back to reference Disutility [online] (2016). York; York Health Economics Consortium; 2016. https://yhec.co.uk/glossary/disutility/
Disutility [online] (2016). York; York Health Economics Consortium; 2016. https://yhec.co.uk/glossary/disutility/
13.
go back to reference Hayes, A., Arima, H., Woodward, M., Chalmers, J., Poulter, N., Hamet, P., & Clarke, P. (2016). Changes in quality of life associated with complications of diabetes: Results from the ADVANCE study. Value in Health: the Journal of the international Society for Pharmacoeconomics and Outcomes Research, 19(1), 36–41. https://doi.org/10.1016/j.jval.2015.10.010CrossRefPubMed
Hayes, A., Arima, H., Woodward, M., Chalmers, J., Poulter, N., Hamet, P., & Clarke, P. (2016). Changes in quality of life associated with complications of diabetes: Results from the ADVANCE study. Value in Health: the Journal of the international Society for Pharmacoeconomics and Outcomes Research, 19(1), 36–41. https://doi.org/10.1016/j.jval.2015.10.010CrossRefPubMed
14.
go back to reference Shao, H., Yang, S., Fonseca, V., Stoecker, C., & Shi, L. (2019). Estimating quality of life decrements due to diabetes complications in the united States: The health utility index (HUI) diabetes complication equation. Pharmacoeconomics, 37(7), 921–929. https://doi.org/10.1007/s40273-019-00775-8CrossRefPubMedPubMedCentral
Shao, H., Yang, S., Fonseca, V., Stoecker, C., & Shi, L. (2019). Estimating quality of life decrements due to diabetes complications in the united States: The health utility index (HUI) diabetes complication equation. Pharmacoeconomics, 37(7), 921–929. https://doi.org/10.1007/s40273-019-00775-8CrossRefPubMedPubMedCentral
15.
go back to reference Keng, M. J., Leal, J., Bowman, L., Armitage, J., & Mihaylova, B. (2022). Decrements in health-related quality of life associated with adverse events in people with diabetes. Diabetes, Obesity & Metabolism, 24(3), 530–538. https://doi.org/10.1111/dom.14610CrossRef
Keng, M. J., Leal, J., Bowman, L., Armitage, J., & Mihaylova, B. (2022). Decrements in health-related quality of life associated with adverse events in people with diabetes. Diabetes, Obesity & Metabolism, 24(3), 530–538. https://doi.org/10.1111/dom.14610CrossRef
16.
go back to reference Mok, C. H., Kwok, H. H. Y., Ng, C. S., Leung, G. M., & Quan, J. (2021). Health state utility values for type 2 diabetes and related complications in East and Southeast Asia: A systematic review and Meta-Analysis. Value in Health: the Journal of the international Society for Pharmacoeconomics and Outcomes Research, 24(7), 1059–1067. https://doi.org/10.1016/j.jval.2020.12.019CrossRefPubMed
Mok, C. H., Kwok, H. H. Y., Ng, C. S., Leung, G. M., & Quan, J. (2021). Health state utility values for type 2 diabetes and related complications in East and Southeast Asia: A systematic review and Meta-Analysis. Value in Health: the Journal of the international Society for Pharmacoeconomics and Outcomes Research, 24(7), 1059–1067. https://doi.org/10.1016/j.jval.2020.12.019CrossRefPubMed
17.
go back to reference Matza, L. S., Stewart, K. D., Lloyd, A. J., Rowen, D., & Brazier, J. E. (2021). Vignette-Based utilities: Usefulness, limitations, and methodological recommendations. Value in Health: the Journal of the international Society for Pharmacoeconomics and Outcomes Research, 24(6), 812–821. https://doi.org/10.1016/j.jval.2020.12.017CrossRefPubMed
Matza, L. S., Stewart, K. D., Lloyd, A. J., Rowen, D., & Brazier, J. E. (2021). Vignette-Based utilities: Usefulness, limitations, and methodological recommendations. Value in Health: the Journal of the international Society for Pharmacoeconomics and Outcomes Research, 24(6), 812–821. https://doi.org/10.1016/j.jval.2020.12.017CrossRefPubMed
18.
go back to reference Stewart, K. D., Johnston, J. A., Matza, L. S., Curtis, S. E., Havel, H. A., Sweetana, S. A., & Gelhorn, H. L. (2016). Preference for pharmaceutical formulation and treatment process attributes. Patient Preference and Adherence, 10, 1385–1399. https://doi.org/10.2147/ppa.S101821CrossRefPubMedPubMedCentral
Stewart, K. D., Johnston, J. A., Matza, L. S., Curtis, S. E., Havel, H. A., Sweetana, S. A., & Gelhorn, H. L. (2016). Preference for pharmaceutical formulation and treatment process attributes. Patient Preference and Adherence, 10, 1385–1399. https://doi.org/10.2147/ppa.S101821CrossRefPubMedPubMedCentral
19.
go back to reference Papaioannou, D., Brazier, J., & Paisley, S. (2010). NICE decision support unit technical support documents. NICE DSU technical support document 9: The identification, review and synthesis of health state utility values from the literature. National Institute for Health and Care Excellence (NICE).
Papaioannou, D., Brazier, J., & Paisley, S. (2010). NICE decision support unit technical support documents. NICE DSU technical support document 9: The identification, review and synthesis of health state utility values from the literature. National Institute for Health and Care Excellence (NICE).
20.
go back to reference Papaioannou, D., Brazier, J., & Paisley, S. (2013). Systematic searching and selection of health state utility values from the literature. Value in Health: the Journal of the international Society for Pharmacoeconomics and Outcomes Research, 16(4), 686–695. https://doi.org/10.1016/j.jval.2013.02.017CrossRefPubMed
Papaioannou, D., Brazier, J., & Paisley, S. (2013). Systematic searching and selection of health state utility values from the literature. Value in Health: the Journal of the international Society for Pharmacoeconomics and Outcomes Research, 16(4), 686–695. https://doi.org/10.1016/j.jval.2013.02.017CrossRefPubMed
21.
go back to reference Page, M. J., Moher, D., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., Chou, R., Glanville, J., Grimshaw, J. M., Hróbjartsson, A., Lalu, M. M., Li, T., Loder, E. W., Mayo-Wilson, E., Mcdonald, S., Mcguinness, L. A., Stewart, L. A., Thomas, J., Tricco, A. C., Welch, V. A., Whiting, P., & Mckenzie, J. E. (2021). PRISMA 2020 explanation and elaboration: Updated guidance and exemplars for reporting systematic reviews. Bmj, 372, n160. https://doi.org/10.1136/bmj.n160CrossRefPubMedPubMedCentral
Page, M. J., Moher, D., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., Chou, R., Glanville, J., Grimshaw, J. M., Hróbjartsson, A., Lalu, M. M., Li, T., Loder, E. W., Mayo-Wilson, E., Mcdonald, S., Mcguinness, L. A., Stewart, L. A., Thomas, J., Tricco, A. C., Welch, V. A., Whiting, P., & Mckenzie, J. E. (2021). PRISMA 2020 explanation and elaboration: Updated guidance and exemplars for reporting systematic reviews. Bmj, 372, n160. https://doi.org/10.1136/bmj.n160CrossRefPubMedPubMedCentral
22.
go back to reference Van Den Akker, O. R., Peters, G. Y., Bakker, C., Carlsson, R., Coles, N. A., Corker, K. S., Feldman, G., Moreau, D., Nordström, T., Pickering, J. S., Riegelman, A., Topor, M., Veggel, N., Yeung, S., & Mellor, D. & Pfeiffer, N. Generalized Systematic Review Registration Form. MetaArXiv. https://doi.org/g5fj
Van Den Akker, O. R., Peters, G. Y., Bakker, C., Carlsson, R., Coles, N. A., Corker, K. S., Feldman, G., Moreau, D., Nordström, T., Pickering, J. S., Riegelman, A., Topor, M., Veggel, N., Yeung, S., & Mellor, D. & Pfeiffer, N. Generalized Systematic Review Registration Form. MetaArXiv. https://doi.org/g5fj
23.
go back to reference Muchadeyi, M. T., Hernandez-Villafuerte, K., & Schlander, M. (2022). Quality appraisal for systematic literature reviews of health state utility values: A descriptive analysis. Bmc Medical Research Methodology, 22(1), 303. https://doi.org/10.1186/s12874-022-01784-6CrossRefPubMedPubMedCentral
Muchadeyi, M. T., Hernandez-Villafuerte, K., & Schlander, M. (2022). Quality appraisal for systematic literature reviews of health state utility values: A descriptive analysis. Bmc Medical Research Methodology, 22(1), 303. https://doi.org/10.1186/s12874-022-01784-6CrossRefPubMedPubMedCentral
24.
go back to reference Tran, A. D., Fogarty, G., Nowak, A. K., Espinoza, D., Rowbotham, N., Stockler, M. R., & Morton, R. L. (2018). A systematic review and meta-analysis of utility estimates in melanoma. British Journal of Dermatology, 178(2), 384–393. https://doi.org/10.1111/bjd.16098CrossRefPubMed
Tran, A. D., Fogarty, G., Nowak, A. K., Espinoza, D., Rowbotham, N., Stockler, M. R., & Morton, R. L. (2018). A systematic review and meta-analysis of utility estimates in melanoma. British Journal of Dermatology, 178(2), 384–393. https://doi.org/10.1111/bjd.16098CrossRefPubMed
25.
go back to reference Feng, J., Zhang, K., Dou, L., Shi, Z., Chen, G., & Li, S. (2024). Health state utility values in patients with ankylosing spondylitis: A systematic review and meta-analysis. Quality of Life Research, 33(9), 2321–2334. https://doi.org/10.1007/s11136-024-03670-8CrossRefPubMed
Feng, J., Zhang, K., Dou, L., Shi, Z., Chen, G., & Li, S. (2024). Health state utility values in patients with ankylosing spondylitis: A systematic review and meta-analysis. Quality of Life Research, 33(9), 2321–2334. https://doi.org/10.1007/s11136-024-03670-8CrossRefPubMed
26.
go back to reference Sterne, J. A., Hernán, M. A., Reeves, B. C., Savović, J., Berkman, N. D., Viswanathan, M., Henry, D., Altman, D. G., Ansari, M. T., Boutron, I., Carpenter, J. R., Chan, A. W., Churchill, R., Deeks, J. J., Hróbjartsson, A., Kirkham, J., Jüni, P., Loke, Y. K., Pigott, T. D., Ramsay, C. R., Regidor, D., Rothstein, H. R., Sandhu, L., Santaguida, P. L., Schünemann, H. J., Shea, B., Shrier, I., Tugwell, P., Turner, L., Valentine, J. C., Waddington, H., Waters, E., Wells, G. A., Whiting, P. F., & Higgins, J. P. (2016). ROBINS-I: A tool for assessing risk of bias in non-randomised studies of interventions. Bmj, 355, i4919. https://doi.org/10.1136/bmj.i4919CrossRefPubMedPubMedCentral
Sterne, J. A., Hernán, M. A., Reeves, B. C., Savović, J., Berkman, N. D., Viswanathan, M., Henry, D., Altman, D. G., Ansari, M. T., Boutron, I., Carpenter, J. R., Chan, A. W., Churchill, R., Deeks, J. J., Hróbjartsson, A., Kirkham, J., Jüni, P., Loke, Y. K., Pigott, T. D., Ramsay, C. R., Regidor, D., Rothstein, H. R., Sandhu, L., Santaguida, P. L., Schünemann, H. J., Shea, B., Shrier, I., Tugwell, P., Turner, L., Valentine, J. C., Waddington, H., Waters, E., Wells, G. A., Whiting, P. F., & Higgins, J. P. (2016). ROBINS-I: A tool for assessing risk of bias in non-randomised studies of interventions. Bmj, 355, i4919. https://doi.org/10.1136/bmj.i4919CrossRefPubMedPubMedCentral
27.
go back to reference Ridderstråle, M., Evans, L. M., Jensen, H. H., Bøgelund, M., Jensen, M. M., Ericsson, Å., & Jendle, J. (2016). Estimating the impact of changes in HbA1c, body weight and insulin injection regimen on health related quality-of-life: A time trade off study. Health and Quality of Life Outcomes, 14, 13. https://doi.org/10.1186/s12955-016-0411-0CrossRefPubMedPubMedCentral
Ridderstråle, M., Evans, L. M., Jensen, H. H., Bøgelund, M., Jensen, M. M., Ericsson, Å., & Jendle, J. (2016). Estimating the impact of changes in HbA1c, body weight and insulin injection regimen on health related quality-of-life: A time trade off study. Health and Quality of Life Outcomes, 14, 13. https://doi.org/10.1186/s12955-016-0411-0CrossRefPubMedPubMedCentral
28.
go back to reference Matza, L. S., Boye, K. S., Yurgin, N., Brewster-Jordan, J., Mannix, S., Shorr, J. M., & Barber, B. L. (2007). Utilities and disutilities for type 2 diabetes treatment-related attributes. Quality of Life Research, 16(7), 1251–1265. https://doi.org/10.1007/s11136-007-9226-0CrossRefPubMed
Matza, L. S., Boye, K. S., Yurgin, N., Brewster-Jordan, J., Mannix, S., Shorr, J. M., & Barber, B. L. (2007). Utilities and disutilities for type 2 diabetes treatment-related attributes. Quality of Life Research, 16(7), 1251–1265. https://doi.org/10.1007/s11136-007-9226-0CrossRefPubMed
29.
go back to reference Matza, L. S., Yurgin, N., Boye, K. S., Malley, K., & Shorr, J. M. (2007). Obese versus non-obese patients with type 2 diabetes: patient-reported outcomes and utility of weight change. Current Medical Research and Opinion, 23(9), 2051–2062. https://doi.org/10.1185/030079907x219454CrossRefPubMed
Matza, L. S., Yurgin, N., Boye, K. S., Malley, K., & Shorr, J. M. (2007). Obese versus non-obese patients with type 2 diabetes: patient-reported outcomes and utility of weight change. Current Medical Research and Opinion, 23(9), 2051–2062. https://doi.org/10.1185/030079907x219454CrossRefPubMed
30.
go back to reference Matza, L. S., Boye, K. S., Stewart, K. D., Davies, E. W., & Paczkowski, R. (2017). Health state utilities associated with attributes of weekly injection devices for treatment of type 2 diabetes. Bmc Health Services Research, 17(1), 774. https://doi.org/10.1186/s12913-017-2648-7CrossRefPubMedPubMedCentral
Matza, L. S., Boye, K. S., Stewart, K. D., Davies, E. W., & Paczkowski, R. (2017). Health state utilities associated with attributes of weekly injection devices for treatment of type 2 diabetes. Bmc Health Services Research, 17(1), 774. https://doi.org/10.1186/s12913-017-2648-7CrossRefPubMedPubMedCentral
31.
go back to reference Mcewan, P., Baker-Knight, J., Ásbjörnsdóttir, B., Yi, Y., Fox, A., & Wyn, R. (2023). Disutility of injectable therapies in obesity and type 2 diabetes mellitus: General population preferences in the UK, Canada, and China. The European Journal of Health Economics, 24(2), 187–196. https://doi.org/10.1007/s10198-022-01470-wCrossRefPubMed
Mcewan, P., Baker-Knight, J., Ásbjörnsdóttir, B., Yi, Y., Fox, A., & Wyn, R. (2023). Disutility of injectable therapies in obesity and type 2 diabetes mellitus: General population preferences in the UK, Canada, and China. The European Journal of Health Economics, 24(2), 187–196. https://doi.org/10.1007/s10198-022-01470-wCrossRefPubMed
32.
go back to reference Lane, S., Levy, A. R., Mukherjee, J., Sambrook, J., & Tildesley, H. (2014). The impact on utilities of differences in body weight among Canadian patients with type 2 diabetes. Current Medical Research and Opinion, 30(7), 1267–1273. https://doi.org/10.1185/03007995.2014.899207CrossRefPubMed
Lane, S., Levy, A. R., Mukherjee, J., Sambrook, J., & Tildesley, H. (2014). The impact on utilities of differences in body weight among Canadian patients with type 2 diabetes. Current Medical Research and Opinion, 30(7), 1267–1273. https://doi.org/10.1185/03007995.2014.899207CrossRefPubMed
33.
go back to reference Rajan, N., Boye, K. S., Gibbs, M., Lee, Y. J., Davey, P., Ball, M., & Babineaux, S. M. (2016). Utilities for type 2 diabetes Treatment-Related attributes in a South Korean and Taiwanese population. Value Health Reg Issues, 9, 67–71. https://doi.org/10.1016/j.vhri.2015.11.006CrossRefPubMed
Rajan, N., Boye, K. S., Gibbs, M., Lee, Y. J., Davey, P., Ball, M., & Babineaux, S. M. (2016). Utilities for type 2 diabetes Treatment-Related attributes in a South Korean and Taiwanese population. Value Health Reg Issues, 9, 67–71. https://doi.org/10.1016/j.vhri.2015.11.006CrossRefPubMed
34.
go back to reference Matza, L. S., Boye, K. S., Jordan, J. B., Norrbacka, K., Gentilella, R., Tiebout, A. R., Browne, C., Orsini Federici, M., Biricolti, G., & Stewart, K. D. (2018). Patient preferences in Italy: Health state utilities associated with attributes of weekly injection devices for treatment of type 2 diabetes. Patient Preference and Adherence, 12, 971–979. https://doi.org/10.2147/ppa.S159620CrossRefPubMedPubMedCentral
Matza, L. S., Boye, K. S., Jordan, J. B., Norrbacka, K., Gentilella, R., Tiebout, A. R., Browne, C., Orsini Federici, M., Biricolti, G., & Stewart, K. D. (2018). Patient preferences in Italy: Health state utilities associated with attributes of weekly injection devices for treatment of type 2 diabetes. Patient Preference and Adherence, 12, 971–979. https://doi.org/10.2147/ppa.S159620CrossRefPubMedPubMedCentral
35.
go back to reference Brennan, V. K., & Dixon, S. (2013). Incorporating process utility into quality adjusted life years: A systematic review of empirical studies. Pharmacoeconomics, 31(8), 677–691. https://doi.org/10.1007/s40273-013-0066-1CrossRefPubMed
Brennan, V. K., & Dixon, S. (2013). Incorporating process utility into quality adjusted life years: A systematic review of empirical studies. Pharmacoeconomics, 31(8), 677–691. https://doi.org/10.1007/s40273-013-0066-1CrossRefPubMed
36.
go back to reference Tremblay, D., Turcotte, A., Touati, N., Poder, T. G., Kilpatrick, K., Bilodeau, K., Roy, M., Richard, P. O., Lessard, S., & Giordano, É. (2022). Development and use of research vignettes to collect qualitative data from healthcare professionals: A scoping review. British Medical Journal Open, 12(1), e057095. https://doi.org/10.1136/bmjopen-2021-057095CrossRef
Tremblay, D., Turcotte, A., Touati, N., Poder, T. G., Kilpatrick, K., Bilodeau, K., Roy, M., Richard, P. O., Lessard, S., & Giordano, É. (2022). Development and use of research vignettes to collect qualitative data from healthcare professionals: A scoping review. British Medical Journal Open, 12(1), e057095. https://doi.org/10.1136/bmjopen-2021-057095CrossRef
37.
go back to reference Lo, S. H., Gorni, K., Sutherland, C. S., Martí, Y., Lloyd, A., & Paracha, N. (2022). Preferences and utilities for treatment attributes in type 2 and Non-ambulatory type 3 spinal muscular atrophy in the united Kingdom. Pharmacoeconomics, 40(Suppl 1), 91–102. https://doi.org/10.1007/s40273-021-01092-9CrossRefPubMed
Lo, S. H., Gorni, K., Sutherland, C. S., Martí, Y., Lloyd, A., & Paracha, N. (2022). Preferences and utilities for treatment attributes in type 2 and Non-ambulatory type 3 spinal muscular atrophy in the united Kingdom. Pharmacoeconomics, 40(Suppl 1), 91–102. https://doi.org/10.1007/s40273-021-01092-9CrossRefPubMed
38.
go back to reference Takumoto, Y., Sasahara, Y., Narimatsu, H., Murata, T., & Akazawa, M. (2022). Health state utility values for metastatic pancreatic cancer using a composite time trade-off based on the vignette-based approach in Japan. Health Econ Rev, 12(1), 63. https://doi.org/10.1186/s13561-022-00413-8CrossRefPubMed
Takumoto, Y., Sasahara, Y., Narimatsu, H., Murata, T., & Akazawa, M. (2022). Health state utility values for metastatic pancreatic cancer using a composite time trade-off based on the vignette-based approach in Japan. Health Econ Rev, 12(1), 63. https://doi.org/10.1186/s13561-022-00413-8CrossRefPubMed
39.
go back to reference Netere, A. K., Ashete, E., Gebreyohannes, E. A., & Belachew, S. A. (2020). Evaluations of knowledge, skills and practices of insulin storage and injection handling techniques of diabetic patients in Ethiopian primary hospitals. Bmc Public Health, 20(1), 1537. https://doi.org/10.1186/s12889-020-09622-4CrossRefPubMedPubMedCentral
Netere, A. K., Ashete, E., Gebreyohannes, E. A., & Belachew, S. A. (2020). Evaluations of knowledge, skills and practices of insulin storage and injection handling techniques of diabetic patients in Ethiopian primary hospitals. Bmc Public Health, 20(1), 1537. https://doi.org/10.1186/s12889-020-09622-4CrossRefPubMedPubMedCentral
40.
go back to reference Negash, Z., Tadiwos, A., Urgessa, E. M., Gebretekle, G. B., Abebe, E., & Fentie, A. M. (2023). Insulin injection practice and health related quality of life among individuals with diabetes at Tikur Anbessa specialized hospital, Ethiopia: A cross-sectional study. Health and Quality of Life Outcomes, 21(1), 38. https://doi.org/10.1186/s12955-023-02123-zCrossRefPubMedPubMedCentral
Negash, Z., Tadiwos, A., Urgessa, E. M., Gebretekle, G. B., Abebe, E., & Fentie, A. M. (2023). Insulin injection practice and health related quality of life among individuals with diabetes at Tikur Anbessa specialized hospital, Ethiopia: A cross-sectional study. Health and Quality of Life Outcomes, 21(1), 38. https://doi.org/10.1186/s12955-023-02123-zCrossRefPubMedPubMedCentral
41.
go back to reference Brazier, J., Akehurst, R., Brennan, A., Dolan, P., Claxton, K., Mccabe, C., Sculpher, M., & Tsuchyia, A. (2005). Should patients have a greater role in valuing health States?? Applied Health Economics and Health Policy, 4(4), 201–208. https://doi.org/10.2165/00148365-200504040-00002CrossRefPubMed
Brazier, J., Akehurst, R., Brennan, A., Dolan, P., Claxton, K., Mccabe, C., Sculpher, M., & Tsuchyia, A. (2005). Should patients have a greater role in valuing health States?? Applied Health Economics and Health Policy, 4(4), 201–208. https://doi.org/10.2165/00148365-200504040-00002CrossRefPubMed
42.
go back to reference Goodwin, E., Davey, A., Green, C., & Hawton, A. (2021). What drives differences in preferences for health States between patients and the public? A qualitative investigation of respondents’ thought processes. Social Science and Medicine, 282, 114150. https://doi.org/10.1016/j.socscimed.2021.114150CrossRefPubMed
Goodwin, E., Davey, A., Green, C., & Hawton, A. (2021). What drives differences in preferences for health States between patients and the public? A qualitative investigation of respondents’ thought processes. Social Science and Medicine, 282, 114150. https://doi.org/10.1016/j.socscimed.2021.114150CrossRefPubMed
43.
go back to reference Stamuli, E. (2011). Health outcomes in economic evaluation: Who should value health? British Medical Bulletin, 97, 197–210. https://doi.org/10.1093/bmb/ldr001CrossRefPubMed
Stamuli, E. (2011). Health outcomes in economic evaluation: Who should value health? British Medical Bulletin, 97, 197–210. https://doi.org/10.1093/bmb/ldr001CrossRefPubMed
Metagegevens
- Titel
- Disutilities of treatment-related attributes for type 2 diabetes mellitus: a systematic review
- Auteurs
-
Shitong Xie
Xinran Liu
Meixuan Li
Jing Wu
- Publicatiedatum
- 25-03-2025
- Uitgeverij
- Springer New York
- Gepubliceerd in
-
Quality of Life Research
Print ISSN: 0962-9343
Elektronisch ISSN: 1573-2649 - DOI
- https://doi.org/10.1007/s11136-025-03945-8